Myeloproliferative Neoplasms

Splenomegaly May Be a Negative Prognostic Factor in Essential Thrombocythemia and Polycythemia Vera

By

Susan Moench, PhD, PA-C

Publish Date January 22, 2020

Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.

Ruxolitinib Plus PEG-IFNα2 for Patients With Polycythemia Vera or Myelofibrosis

By

Vicki Moore, PhD

Publish Date January 21, 2020

The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.

MPN-Directed Therapy Does Not Alter Timing of Clinical Manifestations of Splanchnic Vein Thrombosis

By

Susan Moench, PhD, PA-C

Publish Date December 2, 2019

A retrospective analysis sought to determine the association between myeloproliferative neoplasms, MPN-directed therapy, and development of splanchnic vein thrombosis.

RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera

By

Susan Moench, PhD, PA-C

Publish Date November 11, 2019

Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.

Salvage Therapy With Pegylated Interferon Alfa-2a Benefits High-Risk Myeloproliferative Neoplasms Previously Treated With Hydroxyurea

By

Susan Moench, PhD, PA-C

Publish Date November 4, 2019

This nonrandomized study enrolled more than 100 patients with essential thrombocythemia or polycythemia vera resistant to or intolerant of hydroxyurea to determine if interferon alfa-2a is effective in these patients.